Stock DXCM DEXCOM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

DexCom, Inc. Stock

Equities

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-10-09 pm EDT 		5-day change 1st Jan Change
69.62 USD +0.27% Intraday chart for DexCom, Inc. +3.76% -43.90%
Oct. 08 RBC Capital Adjusts Price Target on DexCom to $120 From $130 MT
Sep. 04 DexCom, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 11:00 AM

Valuation: DexCom, Inc.

(USD)
Capitalization 27.82B P/E ratio 2024 *
42x
P/E ratio 2025 * 34.7x
Enterprise value 29.08B EV / Sales 2024 *
7.25x
EV / Sales 2025 * 6.15x
Free-Float
97.79%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: DexCom, Inc.

Dynamic Chart

Latest news: DexCom, Inc.

RBC Capital Adjusts Price Target on DexCom to $120 From $130 Oct. 08 MT
DexCom, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 11:00 AM Sep. 04
DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium Sep. 04 CI
DexCom Launches OTC Glucose Biosensor Stelo Aug. 26 MT
Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available Aug. 26 CI
Stifel Adjusts Price Target on DexCom to $100 From $90, Maintains Buy Rating Aug. 23 MT
The Stock Market Olympics: Who's on the podium? Aug. 19Our Logo
RBC Adjusts DexCom's Price Target to $130 From $145, Keeps Outperform Rating Aug. 16 MT
DexCom's Glucose Monitoring System Available for Insurance Coverage in Quebec Aug. 14 MT
Insulet inventory pressures cloud annual revenue forecast raise Aug. 08 RE
Baird Adjusts Price Target on DexCom to $82 From $80 Aug. 05 MT
From Boom to Doom Aug. 05Our Logo
Analyst recommendations: Albemarle, Dexcom, Intel, Kellanova, Lloyds... Aug. 05Our Logo
More news

Last Transcript: DexCom, Inc.

Logo DexCom, Inc.
DexCom, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 11:00 AM
Sep. 04
More transcripts

Analysts' recommendations: DexCom, Inc.

RBC Capital Adjusts Price Target on DexCom to $120 From $130 Oct. 08 MT
Stifel Adjusts Price Target on DexCom to $100 From $90, Maintains Buy Rating Aug. 23 MT
RBC Adjusts DexCom's Price Target to $130 From $145, Keeps Outperform Rating Aug. 16 MT
Baird Adjusts Price Target on DexCom to $82 From $80 Aug. 05 MT
Analyst recommendations: Albemarle, Dexcom, Intel, Kellanova, Lloyds... Aug. 05Our Logo
More recommendations

Press Releases: DexCom, Inc.

Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM Oct. 09 PR
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit Oct. 09 PR
Faruqi & Faruqi Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM Oct. 09 PR
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives Oct. 08 BU
Class Action Filed Against DexCom, Inc. (DXCM) - October 21, 2024 Deadline to Join - Contact Levi & Korsinsky Oct. 08 PR
More press releases

News in other languages: DexCom, Inc.

Le Olimpiadi del mercato azionario: chi è sul podio? Aug. 19
De Olympische Beursspelen: wie staat er op het podium? Aug. 18
Die Börsenolympiade: Wer schafft es auf das Siegertreppchen? Aug. 16
Las Olimpiadas bursátiles: ¿Quién sube al podio? Aug. 16
La RAMQ élargit sa couverture provinciale pour inclure le Dexcom G7, offrant ainsi le système de SCG de nouvelle génération à un plus grand nombre de Québécois Aug. 14
More news

Quotes and Performance

1 day+0.27%
1 week+5.48%
Current month+3.85%
1 month+1.47%
3 months-37.26%
6 months-50.25%
Current year-43.90%
More quotes

Course Extremes

1 week
65.58
Extreme 65.58
69.73
1 month
64.76
Extreme 64.76
72.34
Current year
62.34
Extreme 62.34
142.00
1 year
62.34
Extreme 62.34
142.00
3 years
62.34
Extreme 62.34
164.86
5 years
36.31
Extreme 36.3075
164.86
10 years
9.73
Extreme 9.7275
164.86
More quotes

Managers and Directors: DexCom, Inc.

Director TitleAgeSince
Kevin Sayer CEO
 Chief Executive Officer 66 07-10-31
Jereme Sylvain DFI
 Director of Finance/CFO 44 18-08-31
Girish Naganathan CTO
 Chief Tech/Sci/R&D Officer 47 22-09-30
Manager TitleAgeSince
Kevin Sayer CEO
 Chief Executive Officer 66 07-10-31
Eric Topol BRD
 Director/Board Member 69 09-07-08
Nick Augustinos BRD
 Director/Board Member 65 09-11-19
More insiders

ETFs: DexCom, Inc.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
1.46% 19 M€ +11.52% -
HARBOR HEALTH CARE UCITS ETF ACC - USD ETF Harbor Health Care UCITS ETF Acc - USD
1.04% 14 M€ -0.88% -
More ETFs: DexCom, Inc.

Other Medical Equipment, Supplies & Distribution

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
DEXCOM, INC. Stock DexCom, Inc.
+0.27%+5.48%-16.34%-47.37%27.82B
ABBOTT LABORATORIES Stock Abbott Laboratories
+1.15%+2.10%+19.68%-2.06%199B
MEDTRONIC PLC Stock Medtronic plc
+0.24%-1.83%+16.07%-29.47%113B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
+0.44%-1.43%-9.23%-0.16%68.55B
HOYA CORPORATION Stock Hoya Corporation
+2.52%+6.68%+43.21%+29.67%48.6B
CENCORA, INC. Stock Cencora, Inc.
+0.16%-1.37%+20.29%+85.27%43.28B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
-0.06%-1.83%+34.10%+4.71%30.8B
TERUMO CORPORATION Stock Terumo Corporation
+1.07%+7.50%+51.81%+17.12%29.03B
STERIS PLC Stock STERIS plc
-0.03%-3.66%+1.30%+3.49%22.41B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.01%-4.43%-24.11%-29.63%20.78B
Average +0.58%-0.25%+13.68%+3.16% 60.38B
Weighted average by Cap. +0.75%-0.70%+16.09%+0.27%
See all sector performances

Financials

(USD)
2024 *2025 *
Net sales 4.01B 4.63B
Net income 670M 806M
Net Debt 1.26B 666M
More financial data * Estimated data

Company Profile

Logo DexCom, Inc.
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 72.5% of net sales.
Employees
9,550
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-10-23 - Q3 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
24-10-09 69.62 $ +0.27% 2,625,079
24-10-08 69.43 $ +1.18% 3,944,442
24-10-07 68.62 $ +0.75% 3,605,425
24-10-04 68.11 $ +3.70% 6,336,526
24-10-03 65.68 $ -2.12% 3,457,495

Delayed Quote Nasdaq, October 09, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

income-statement-evolution-chart DEXCOM-INC More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart DEXCOM-INCMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
69.43USD
Average target price
95.69USD
Spread / Average Target
+37.82%
Consensus
Profit revisions
estimates-change-chart DEXCOM-INC Estimate revisions

Quarterly earnings, Rate of surprise

quality-estimates-chart DEXCOM-INC Company calendar
  1. Stock Market
  2. Equities
  3. DXCM Stock